News FDA backs Novartis' Gilenya in paediatric MS First disease modifying therapy approved in paediatric MS
News e-Therapeutics and C4XD research Parkinson's drugs Biotechs search for new treatments for incurable disease
News FDA probes Parkinson's drug safety, Acadia's shares collapse FDA under pressure to act following press reports
News Lilly and Alder showcase latest migraine drug data Lilly and Alder take on the might of Novartis and Amgen
News FDA advisers back GW's Epidiolex for rare epilepsy UK firm's potential blockbuster on course for approval
News RevMed hails first-line data with pancreatic cancer drug Revolution Medicine's fast-growing pan-RAS inhibitor Rasonque has generated exciting results as a first-line treatment for pancreatic cancer.
Sales & Marketing Sponsored Securing your ROI: Turning post-acquisition integration into... Join Forinnovia and Little Cube Consulting for a webinar on securing post-acquisition ROI.